Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1268MR)

This product GTTS-WQ1268MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1268MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11292MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-522
GTTS-WQ352MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ7326MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ10313MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ5993MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ11469MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ722MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA A-623
GTTS-WQ1950MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGS15C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW